Byung Ho Nam
YOU?
Author Swipe
Effects of a case-based simulation fever management education program for parents of hospitalized children in South Korea: a quasi-experimental study Open
Purpose: Because fever is a common symptom in children, parents must have accurate knowledge and management ability about it to be able to provide appropriate management. This study aimed to develop a fever management education program, in…
View article: The impact of direct health facility financing on MNCH service provision: results from a comparative, before-after study in Pwani Region, Tanzania
The impact of direct health facility financing on MNCH service provision: results from a comparative, before-after study in Pwani Region, Tanzania Open
Background Pwani Regional Secretariat in Tanzania implemented the Maternal, Neonatal, and Child Health Project (2016–2022) through Direct Health Facility Financing (DHFF), which allocates funds directly to health facilities. This study ass…
Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer Open
ClinicalTrials.gov Identifier: NCT01091636.
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01) Open
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of a…
ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer Open
Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors Open
Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.